Pathology Industry in China: Market Research Reports, Statistics and Analysis

China: Demographic Snapshot, February 2013

... Model to use strains as the main outcome variable, income as a predictor and self-rated general health status, depression and self-efficacy as mediators. Results high levels of strains were significantly ...

Company Report: Pathology In China And India For Year 2012

... Million (2011: approximately rmb140.3 Million). The increase in revenue of the group was primarily attributed to the growth of congenital heart diseases business and peripheral vascular diseases business ...

Entremed Inc. - Investment Analysis, December 2012

Company Report: Pathology In China For Year 2012

... Drug stores to ensure sales growth momentum of this product. The Shen miao Trademark was certified as a China famous trademark . - 8 - Emerging products huang qi injection For treatment of viral ...

Company Report: Pathology In China, The United States And Canada ...

... Of the world primarily due to growth of existing distributors in europe; o infectious disease sales have decreased 70%, or $0.4 Million compared to 2011, due to the transition from 3m to fisher health ...

Company Report: Pathology In China For Year 2013

... In the areas of cns, endocrine & metabolic, infectious diseases, and musculoskeletal diseases. The company has filed nda to the sfda for three cns drugs and two infectious diseases drugs. The current market ...

Pharmaceutical Sector In China

The Chinese Pharmaceutical Industry Analysis

... Orphan drug designation granted for melphalan in the treatment of ocular melanoma, cutaneous melanoma and metastatic neuroendocrine tumors, as well as for doxorubicin in the treatment of hcc Provides ...

Pharmaceutical Business Analysis In Canada And China

... Med 2006;38:52-63 these features lead to type 2 diabetes and cardiovascular disease visceral obesity is associated with a cluster of metabolic abnormalities often described as the Metabolic syndrome ...